Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

StageZero Life Sciences Ltd T.SZLS

Alternate Symbol(s):  SZLSF

StageZero Life Sciences, Ltd. is a Canada-based vertically integrated healthcare company. The Company is engaged in improving the early detection and management of cancer and other chronic diseases through diagnostics and telehealth programs that provide clinical interventions to assist patients who have cancer (COC Protocol), and help patients reduce the risk of developing late-stage disease (AVRT). Its test, Aristotle, is the first mRNA multi-cancer panel for simultaneously screening for multiple cancers from a single sample of blood with high sensitivity and specificity for each cancer. Aristotle uses mRNA technology to identify the molecular signatures of multiple cancer types and is built on the Company's patented technology platform, the Sentinel Principle. The Care Oncology Clinic offers a supervised treatment regimen (the COC Protocol) for people diagnosed with cancer of any type or stage. Its ColonSentry is a proprietary blood test for screening for Colorectal Cancer.


TSX:SZLS - Post by User

Post by Stockish12on Jan 07, 2021 8:48pm
301 Views
Post# 32251028

SZLS MANAGEMENT LACKS CAPACITY

SZLS MANAGEMENT LACKS CAPACITYThere are some very daft investors on this platform.
We will be lucky if Tripp delivers a $10million revenue from Aristotle but some clowns on here talking about billion dollar valuations. LMFAO 
Have you seen CEOs and board members of billion dollar companies? Do they sound incoherent and look like Tripp?
What a joke.

We will be lucky if this stock ever sets a new 52wk high.

Tripp is a joke. 

My advice. Be prepared for Tripp telling you Aristotle is further delayed (this would not be new). Have money on hand to average down some more if the Dec fins come out before Aristotle cos it will be trash as usual.

I sent Tripp and the IR an email for them to consider a replacement for Tripp as CEO. That dude does not have the capacity to achieve much for this company.

Did you all see CBDT PR? talking to airlines for their covid test kits?

SZLS made its saliva testing since October and its in achieved nothing. CBDT already got $5.5million in a shorter time for their home testing kit and trying to get major deals with airlines.

Same way SZLS could not market covid tests is the same way they will have a good product like aristotle but not know how to market it. 
<< Previous
Bullboard Posts
Next >>